Microbot Medical Inc. is a medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system designed to maneuver guidewires and over-the-wire devices, such as microcatheters within the body's vasculature for use in cardiovascular, peripheral, endovascular, and neurovascular operations. It also provides NovaCross, an intellectual property and technology in the field of intraluminal revascularization devices with anchoring mechanism and integrated microcatheter. The company has a collaboration agreement with Corewell Health for the development of LIBERTY endovascular robotic system; and Emory University, in connection with autonomous robotics in endovascular procedures. Microbot Medical Inc. was founded in 2010 and is based in Hingham, Massachusetts.…
Microbot Medical Reports Q3 Revenue of $72,000 as LIBERTY System Procedure Volumes Rise 44%
Microbot Medical (NASDAQ: MBOT) is listed on Nasdaq, where its shares trade in USD. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 43 employees.
The shares were at 0.6800 USD on 20 November 2026, down 66.8% over 52 weeks. Its 52-week range is 0.5222 USD to 2.860 USD: the price is 76.2% below the high and 30.2% above the low.
Its market capitalisation is 45.67M USD.
Microbot Medical reports return on equity of -16.9%.
It holds more cash than debt, a net cash position of 60.99M USD. Its Piotroski F-score is 4 out of 9, an average reading of its financial health.